ROCURONIUM
GENERAL DRUG CLASSIFICATION: PNS-Anticholinergic agents-muscarinic antagonists
CHEMICAL NAME: 1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-14-(acetyloxy)-5-hydroxy-2,15-
dimethyl-4-(morpholin-4-yl)tetracyclo[[Link]²,⁷.0¹¹,¹⁵]heptadecan-13-yl]-1-(prop-
2-en-1-yl)pyrrolidin-1-ium [1]
GENERIC NAME: Rocuronium bromide [1]
BRAND NAME: Esmeron [2]
INDICATIONS: For inpatients and outpatients as an adjunct to general anesthesia to facilitate both
rapid sequence and routine tracheal intubation, and to provide skeletal muscle
relaxation during surgery or mechanical ventilation. [1]
PHARMACOKINETICS: Absorption: Poorly absorbed from the GI tract [1]
Distribution: no available data
Metabolism: Rocuronium is metabolized to a less active metabolite, 17-desacetyl-
rocuronium, and is eliminated primarily by the liver. [1]
Excretion: Studies of distribution, metabolism, and excretion in cats and dogs
indicate that rocuronium is eliminated primarily by the liver. [1]
PHARMACODYNAMICS: Rocuronium acts by competing for cholinergic receptors at the motor end-plate.
This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine
and edrophonium. Competitively binds to nicotinic cholinergic receptors which
prevent depolarization, calcium ions are not released and muscle contraction does
not occur. It has been assumed that non-depolarizing agents bind to post junctional
("curare") receptors and could interfere with the sodium and potassium flux,
responsible for depolarization and repolarization of the membranes during
contraction of the muscle. [1]
DRUG INTERACTIONS: Halogenated volatile anesthetics potentiate the neuromuscular block of
Rocuronium Bromide. [3]
Corticosteroids long term used may result in prolonged duration of neuromuscular
block or myopathy. [3]
aminoglycoside, lincosamide, polypeptide and acylamino-penicillin
antibiotics, quinidine, quinine and magnesium salts recurarization has been
reported. [3]
Administration of other non-depolarizing neuromuscular blocking agents may
produce attenuation or potentiation of the neuromuscular block, depending on the
order of administration and the neuromuscular blocking agent used. [3]
Suxamethonium may produce potentiation or attenuation of the neuromuscular
blocking effect. [3]
LABORATORY No data available
INTERFERENCES:
[1]
REFERENCES: Desmopressin - DrugBank. [Link].
[Link] Published 2018. Accessed November
21, 2018.
[2]
Rocuronium bromide: Indication, Dosage, Side Effect, Precaution | [Link]
Philippines. [Link]. [Link]
%20bromide?mtype=generic. Published 2018. Accessed 2018.
[3]
Esmeron Dosage & Drug Information | [Link] Philippines. [Link].
[Link] Published 2018. Accessed
2018.